Florida 2023 Regular Session

Florida House Bill H0967 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2		-	~~ENROLLED~~
3		-	CS/HB 967 2023 ~~Legislature~~
	2	+
	3	+	CS/HB 967 2023
4	4
5	5
6	6
7	7		CODING: Words stricken are deletions; words underlined are additions.
8		-	hb0967-~~02-er~~
	8	+	hb0967-01-c1
9	9		Page 1 of 3
10	10		F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
11	11
12	12
13	13
14		-	1
	14	+	A bill to be entitled 1
15	15		An act relating to Medicaid coverage of continuous 2
16	16		glucose monitors; creating s. 409.9063, F.S.; defining 3
17	17		the term "continuous glucose monitor"; requiring the 4
18	18		Agency for Health Care Administration, subject to the 5
19	19		availability of funds and certain limitations and 6
20	20		directions, to provide coverage for continuous glucose 7
21	21		monitors for certain Medicaid recipients; providing 8
22	22		construction; providing requirements for Medi caid 9
23	23		recipients to continue receiving coverage for their 10
24	24		continuous glucose monitors; requiring the agency to 11
25	25		seek federal approval for implementation of the act, 12
26	26		if needed; requiring the agency to include the rate 13
27	27		impact of the act in certain rates that b ecome 14
28	28		effective on a specified date; providing an effective 15
29	29		date. 16
30	30		17
31	31		Be It Enacted by the Legislature of the State of Florida: 18
32	32		19
33	33		Section 1. Section 409.9063, Florida Statutes, is created 20
34	34		to read: 21
35	35		409.9063 Coverage of continuous glucose monitors for 22
36	36		Medicaid recipients. — 23
37	37		(1) As used in this section, the term "continuous glucose 24
38	38		monitor" means an instrument or a device designed for the 25
39		-	~~ENROLLED~~
40		-	CS/HB 967 2023 ~~Legislature~~
	39	+
	40	+	CS/HB 967 2023
41	41
42	42
43	43
44	44		CODING: Words stricken are deletions; words underlined are additions.
45		-	hb0967-~~02-er~~
	45	+	hb0967-01-c1
46	46		Page 2 of 3
47	47		F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
48	48
49	49
50	50
51	51		purpose of aiding in the treatment of diabetes by measuring 26
52	52		glucose levels on demand or at set intervals through a s mall, 27
53	53		electronic sensor that slightly penetrates a person's skin when 28
54	54		applied and that is designed to remain in place and active for 29
55	55		at least 7 days. 30
56	56		(2) Subject to the availability of funds and subject to 31
57	57		any limitations or directions provided in the Ge neral 32
58	58		Appropriations Act, the agency must provide coverage for a 33
59	59		continuous glucose monitor under the Medicaid pharmacy benefit 34
60	60		for the treatment of a Medicaid recipient if: 35
61	61		(a) The recipient has been diagnosed by his or her primary 36
62	62		care physician, or an other licensed health care practitioner 37
63	63		authorized to make such diagnosis, with Type 1 diabetes, Type 2 38
64	64		diabetes, gestational diabetes, or any other type of diabetes 39
65	65		that may be treated with insulin; and 40
66	66		(b) A health care practitioner with the applicable 41
67	67		prescribing authority has prescribed insulin to treat the 42
68	68		recipient's diabetes and a continuous glucose monitor to assist 43
69	69		the recipient and practitioner in managing the recipient's 44
70	70		diabetes. 45
71	71		(3) Coverage under this section includes the cost of any 46
72	72		necessary repairs or replacement parts for the continuous 47
73	73		glucose monitor. 48
74	74		(4) To qualify for continued coverage under this section, 49
75	75		the Medicaid recipient must participate in follow -up care with 50
76		-	~~ENROLLED~~
77		-	CS/HB 967 2023 ~~Legislature~~
	76	+
	77	+	CS/HB 967 2023
78	78
79	79
80	80
81	81		CODING: Words stricken are deletions; words underlined are additions.
82		-	hb0967-~~02-er~~
	82	+	hb0967-01-c1
83	83		Page 3 of 3
84	84		F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
85	85
86	86
87	87
88	88		his or her treating health care practitioner, in person or 51
89	89		through telehealth, at least once every 6 months during the 52
90	90		first 18 months after the first prescription of the continuous 53
91	91		glucose monitor for the recipient has been issued under this 54
92	92		section, to assess the efficacy of using the monitor for 55
93	93		treatment of his or her diabetes. After the first 18 months, 56
94	94		such follow-up care must occur at least once every 12 months. 57
95	95		(5) The agency shall seek federal approval, if needed, for 58
96	96		the implementation of this section. 59
97	97		Section 2. The Agency for Health Care Administratio n shall 60
98	98		include the rate impact of this act in the Medicaid managed 61
99	99		medical assistance program and long -term care managed care 62
100	100		program rates, as applicable, that take effect on October 1, 63
101	101		2023. 64
102	102		Section 3. This act shall take effect October 1, 2023. 65